{"url_path":"/sec/incy/8-k/2026-06-08/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-08","source_url":"https://www.sec.gov/Archives/edgar/data/879169/0000879169-26-000040-index.html","accession_number":"0000879169-26-000040","cik":"0000879169","ticker":"INCY","issuer_name":"INCYTE CORP","edgar_url":"https://www.sec.gov/Archives/edgar/data/879169/0000879169-26-000040-index.html","primary_entity_key":"0000879169","primary_entity_name":"INCYTE CORP"},"word_count":69,"has_tables":true,"body_markdown":"Item 8.01 Other Events.\n\nOn June 8, 2026, Incyte Corporation (the “Company”) issued a press release announcing it had entered into a definitive agreement to acquire Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics, LLC (“Vega Therapeutics”). A copy of the Company’s press release announcing its entry into the definitive agreement to acquire Vega Therapeutics is attached as Exhibit 99.1 to this Current Report on Form 8-K."}